☆ 4.4 Editorial Material

Opening the Door for Immune Oncology Studies in Invasive Lobular Breast Cancer

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)

Journal

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE

Volume 110, Issue 7, Pages 696-698

Publisher

OXFORD UNIV PRESS INC

DOI: 10.1093/jnci/djy014

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

The Genomic Landscape of Lobular Breast Cancer

Amy E. McCart Reed, Samuel Foong, Jamie R. Kutasovic, Katia Nones, Nicola Waddell, Sunil R. Lakhani, Peter T. Simpson

Summary: This study presents a meta-analysis of invasive lobular carcinoma (ILC) sequencing data to provide a unified resource for ILC research, confirming the prognostic significance of clinico-pathology features and genomics in this unique tumor type. The genomic landscape significantly impacts the variable natural history and overall survival of ILC patients.

CANCERS (2021)

Add to Collection

Article Oncology

Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making

Daniela Cocco, Ayat ElSherif, Matthew D. Wright, Marcus S. Dempster, Megan L. Kruse, Hong Li, Stephanie A. Valente

Summary: Invasive lobular carcinoma is a unique subset of cancer with diagnostic staging challenges. The study results support the use of MRI for accurate tumor staging and improved detection of multicentricity and bilaterality. However, clinicians should be aware of the higher likelihood of occult lymph node involvement with ILC and subsequent early metastasis.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Oncology

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

Sayali Onkar, Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin, April Sagan, Marion Joy, Hatice U. Osmanbeyoglu, Katherine L. Pogue-Geile, Priscilla F. McAuliffe, Peter C. Lucas, George C. Tseng, Adrian V. V. Lee, Tullia C. Bruno, Steffi Oesterreich, Dario A. A. Vignali

Summary: Using single-cell and high-dimensional profiling, this study investigates the immune biology of estrogen receptor-positive (ER+) breast cancer in women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). The results show that macrophages, rather than T cells, are the dominant immune cells infiltrating the tumor bed in both IDC and ILC. Furthermore, an interplay between macrophages and T cells is associated with longer disease-free survival in IDC but not ILC.

NATURE CANCER (2023)

Add to Collection

Article Multidisciplinary Sciences

Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer

Rusen Cosar, Necdet Sut, Sernaz Topaloglu, Ebru Tastekin, Dilek Nurlu, Talar Ozler, Eylul Senodeyici, Melisa Dedeli, Mert Chousein, Irfan Cicin

Summary: This study compared the clinical features and prognosis of invasive lobular carcinoma patients and found that the invasive lobular special type had the worst prognosis, suggesting a need for reclassification and reconsideration of treatment methods.

PLOS ONE (2023)

Add to Collection

Article Oncology

A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer

Agostina Nardone, Xintao Qiu, Sandor Spisak, Zsuzsanna Nagy, Ariel Feiglin, Avery Feit, Gabriela Cohen Feit, Yingtian Xie, Alba Font-Tello, Cristina Guarducci, Francisco Hermida-Prado, Sudeepa Syamala, Klothilda Lim, Miguel Munoz Gomez, Matthew Pun, MacIntosh Cornwell, Weihan Liu, Aysegul Ors, Hisham Mohammed, Paloma Cejas, Jane B. Brock, Matthew L. Freedman, Eric P. Winer, Xiaoyong Fu, Rachel Schiff, Henry W. Long, Otto Metzger Filho, Rinath Jeselsohn

Summary: Most invasive lobular breast cancers (ILC) are of the luminal A subtype and are strongly hormone receptor-positive. However, ILC is relatively resistant to tamoxifen and associated with inferior long-term outcomes compared with invasive ductal cancers (IDC). In this study, the researchers found that ILC had a unique chromatin state and FOXA1-ER axis that promoted tumor progression, offering a novel mechanism of tamoxifen resistance. These results highlight the importance of conducting clinical trials dedicated to patients with ILC to optimize treatments in this breast cancer subtype.

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells

Fangyuan Chen, Kai Ding, Nolan Priedigkeit, Ashuvinee Elangovan, Kevin M. Levine, Neil Carleton, Laura Savariau, Jennifer M. Atkinson, Steffi Oesterreich, Adrian V. Lee

Summary: This study revealed transcriptional heterogeneity in breast cancer cell lines and the significant role of E-cadherin depletion in contributing to the molecular features of invasive lobular breast carcinoma.

CANCER RESEARCH (2021)

Add to Collection

Review Oncology

Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer

K. Van Baelen, T. Geukens, M. Maetens, V Tjan-Heijnen, C. J. Lord, S. Linn, F-C Bidard, F. Richard, W. W. Yang, R. E. Steele, S. J. Pettitt, C. Van Ongeval, M. De Schepper, E. Isnaldi, I Nevelsteen, A. Smeets, K. Punie, L. Voorwerk, H. Wildiers, G. Floris, A. Vincent-Salomon, P. W. B. Derksen, P. Neven, E. Senkus, E. Sawyer, M. Kok, C. Desmedt

Summary: ILC is a unique type of breast cancer with distinct pathological and biological features, leading to differences in diagnosis, treatment response, resistance, and targets compared to NST.

ANNALS OF ONCOLOGY (2022)

Add to Collection

Review Oncology

Invasive lobular carcinoma: an understudied emergent subtype of breast cancer

Jason A. Mouabbi, Amy Hassan, Bora Lim, Gabriel N. Hortobagyi, Debasish Tripathy, Rachel M. Layman

Summary: Invasive lobular carcinoma (ILC) is the second most common subtype of breast cancer, with conflicting outcomes compared to invasive ductal carcinoma (IDC). Recent studies have shown that ILC and IDC are distinct entities.

BREAST CANCER RESEARCH AND TREATMENT (2022)

Add to Collection

Article Medicine, General & Internal

Circulating tumour DNA characterisation of invasive lobular carcinoma in patients with metastatic breast cancer

Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli

Summary: This study analyzed genomic differences in circulating tumor DNA (ctDNA) among patients with invasive lobular carcinoma (ILC), invasive ductal carcinoma (IDC), and mixed histology. The results showed that ILC was associated with specific HR+ HER2 negative and HER2 low characteristics. Higher levels of single nucleotide variations (SNVs) were observed in ILC patients compared to IDC or mixed histology patients. Mutations in CDFII, ERBB2, and PTEN genes were significantly associated with HR+ HER2 negative ILC. Additionally, mutations in the PI3K pathway genes were more common in ILC patients. These findings have implications for histologic classification and precision medicine treatment.

EBIOMEDICINE (2022)

Add to Collection

Article Oncology

Association of variably methylated tumour DNA regions with overall survival for invasive lobular breast cancer

Medha Suman, Pierre-Antoine Dugue, Ee Ming Wong, JiHoon Eric Joo, John L. Hopper, Tu Nguyen-Dumont, Graham G. Giles, Roger L. Milne, Catriona McLean, Melissa C. Southey

Summary: This study investigated the genome-wide variability of DNA methylation levels across invasive lobular breast cancer (ILBC) tumors and found that methylation at several genes may serve as a potential biomarker for survival in ILBC patients.

CLINICAL EPIGENETICS (2021)

Add to Collection

Review Oncology

Lobular Breast Cancer: A Review

Natalie Wilson, Alastair Ironside, Anna Diana, Olga Oikonomidou

Summary: Invasive lobular carcinoma accounts for a small percentage of breast cancers but has distinctive biological and molecular features that make diagnosis and treatment challenging. This type of cancer is less responsive to chemotherapy and often requires endocrine therapy. Understanding the unique biology of lobular breast carcinoma is crucial for guiding future treatment strategies.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy

Mukesh Gangar, Sandeep Goyal, Digambar Raykar, Princy Khurana, Ashwita M. Martis, Avijit Goswami, Ishani Ghoshal, Yadav Nagare, Santosh Raikar, Apurba Mukherjee, Rajath Cyriac, Jean-Francois Paquin, Aditya Kulkarni, Ketul Patel

Summary: ENPP1 is an attractive therapeutic target for cancer immunotherapy, acting as a critical phosphodiesterase that negatively regulates the STING pathway. Novel non-nucleotidic thioguanine based small molecule inhibitors of ENPP1 have shown promising in vitro potency and potent anti-tumor response in vivo, providing a good starting point for potentially effective cancer immunotherapy agents.

BIOORGANIC CHEMISTRY (2022)

Add to Collection

Article Oncology

Prognostic Utility of Breast Cancer Index to Stratify Distant Recurrence Risk in Invasive Lobular Carcinoma

Raquel Nunes, Tal Sella, Kai Treuner, Jennifer M. Atkinson, Jenna Wong, Yi Zhang, Pedro Exman, David Dabbs, Andrea L. Richardson, Catherine A. Schnabel, Dennis C. Sgroi, Steffi Oesterreich, Ashley Cimino-Mathews, Otto Metzger

Summary: The study evaluated the prognostic utility of the Breast Cancer Index (BCI) for assessing the risk of distant recurrence (DR) in hormone receptor-positive invasive lobular carcinoma (ILC) patients. BCI was found to be a significant independent prognostic factor for overall 10-year, early, and late DR, adding value beyond clinicopathologic characteristics.

CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

The term classic invasive lobular carcinoma of the breast defines breast malignancies of vastly different nature

Laszlo Tabar, Peter B. Dean, Amy Ming-Fang Yen, Wendy Yi-Ying Wu, Miklos Tarjan, F. Lee Tucker, Tony Hsiu-Hsi Chen, Andras Voros

Summary: This study describes in detail a special type of breast cancer, invasive lobular carcinoma, which is confined to the terminal ductal lobular units (TDLUs) and differs considerably from the extensive classic invasive lobular carcinoma. The study found striking differences in subgross histopathology and mammographic appearance between these two types of tumors, as well as significant differences in long-term outcomes.

EUROPEAN JOURNAL OF RADIOLOGY (2023)

Add to Collection

Article Oncology

Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer

John Alexander, Odette Mariani, Celine Meaudre, Laetitia Fuhrmann, Hui Xiao, Kalnisha Naidoo, Andrea Gillespie, Ioannis Roxanis, Anne Vincent-Salomon, Syed Haider, Rachael Natrajan

Summary: This study found that invasive lobular breast cancers with heterogeneous E-cadherin expression are composed of different components with a common ancestor. CDH1 gene mutations and loss of E-cadherin protein expression are characteristic of these tumors. Regardless of E-cadherin protein expression, these tumors should be considered part of the spectrum of invasive lobular breast cancers.

CANCERS (2022)

Add to Collection

Meeting Abstract Oncology

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study-A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)

Caio Max Sao Pedro Rocha Lima, Greg Yothers, Samuel A. Jacobs, Hanna Kelly Sanoff, Deirdre Jill Cohen, Katherine A. Guthrie, Norah Lynn Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles David Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George, Michael J. Overman

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

MALT1 Is a Targetable Driver of Epithelial-to-Mesenchymal Transition in Claudin-Low, Triple-Negative Breast Cancer

Jia-Ying Lloyd Lee, Prasanna Ekambaram, Neil M. Carleton, Dong Hu, Linda R. Klei, Zongyou Cai, Max Myers, Nathaniel E. Hubel, Lidija Covic, Sameer Agnihotri, Daniel Krappmann, Frederic Bornancin, Adrian Lee, Steffi Oesterreich, Linda M. McAllister-Lucas, Peter C. Lucas

Summary: MALT1 is the effector protein in the CARMA/Bcl10/MALT1 inflammatory signaling pathways, playing a key role in EMT in immune cells and solid tumors, particularly in TNBC, where its signaling blockade can partially reverse EMT.

MOLECULAR CANCER RESEARCH (2022)

Add to Collection

Meeting Abstract Oncology

A novel luminal invasive lobular carcinoma cell line model

Ashuvinee Elangovan, Emily A. Bossart, Ahmed Basudan, Nilgun Tasdemir, Osama Shiraz Shah, Kai Ding, Carolin Meier, Tanya Heim, Lori Miller, Tiantong Liu, Shannon L. Puhalla, Grzegorz Gurda, Peter C. Lucas, Priscilla F. McAuliffe, Jennifer M. Atkinson, Adrian V. Lee, Steffi Oesterreich

CANCER RESEARCH (2022)

Add to Collection

Meeting Abstract Oncology

Potential role of the antibody-dependent cellular phagocytosis (ADCP) in tumors achieving pCR in NRG Oncology/NSABP B-52

Katherine L. Pogue-Geile, Ying Wang, Huichen Feng, Corey Lipchick, Patrick Gavin, Rim S. Kim, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Sandra M. Swain, Eleftherios Mamounas, Charles E. Geyer, Priya Rastogi, Peter C. Lucas, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Mothaffar F. Rimawi

CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Mixed invasive ductal lobular carcinoma is clinically and pathologically more similar to invasive lobular than ductal carcinoma

Azadeh Nasrazadani, Yujia Li, Yusi Fang, Osama Shah, Jennifer M. Atkinson, Joanna S. S. Lee, Priscilla F. McAuliffe, Rohit Bhargava, George Tseng, Adrian V. V. Lee, Peter C. Lucas, Steffi Oesterreich, Norman Wolmark

Summary: This study describes the clinicopathologic characteristics of mixed invasive ductal lobular carcinoma (mDLC) and finds that mDLC is clinically more similar to invasive lobular carcinoma (ILC) than invasive ductal carcinoma (IDC). Successful breast-conserving surgery rates after neoadjuvant chemotherapy are higher in mDLC patients compared to ILC patients. The metastatic patterns of mDLC show characteristics of both IDC and ILC.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik

Summary: In patients with residual invasive breast cancer, T-DM1 reduces the risk of disease recurrence or death compared to trastuzumab. The efficacy of T-DM1 is independent of HER2 expression level and immune activation.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Review Oncology

The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes

Sayali S. Onkar, Neil M. Carleton, Peter C. Lucas, Tullia C. Bruno, Adrian V. Lee, Dario A. A. Vignali, Steffi Oesterreich

Summary: Breast cancer is a diverse disease with different subtypes, and recent advances have provided new insights into the complex interactions between tumor and immune cells. While immunotherapy has shown limited promise for breast cancer, this review aims to identify opportunities for tailored immunotherapy agents based on the specific features of each breast cancer subtype.

CANCER DISCOVERY (2023)

Add to Collection

Correction Oncology

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment (Mar, 10.1038/s43018-023-00527-w, 2023)

Sayali Onkar, Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin, April Sagan, Marion Joy, Hatice U. Osmanbeyoglu, Katherine L. Pogue-Geile, Priscilla F. McAuliffe, Peter C. Lucas, George C. Tseng, Adrian V. Lee, Tullia C. Bruno, Steffi Oesterreich, Dario A. A. Vignali

NATURE CANCER (2023)

Add to Collection

Article Oncology

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

Sayali Onkar, Jian Cui, Jian Zou, Carly Cardello, Anthony R. Cillo, Mostofa Rafid Uddin, April Sagan, Marion Joy, Hatice U. Osmanbeyoglu, Katherine L. Pogue-Geile, Priscilla F. McAuliffe, Peter C. Lucas, George C. Tseng, Adrian V. V. Lee, Tullia C. Bruno, Steffi Oesterreich, Dario A. A. Vignali

Summary: Using single-cell and high-dimensional profiling, this study investigates the immune biology of estrogen receptor-positive (ER+) breast cancer in women with invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC). The results show that macrophages, rather than T cells, are the dominant immune cells infiltrating the tumor bed in both IDC and ILC. Furthermore, an interplay between macrophages and T cells is associated with longer disease-free survival in IDC but not ILC.

NATURE CANCER (2023)

Add to Collection

Meeting Abstract Endocrinology & Metabolism

Tumor-Intrinsic and -Extrinsic Mechanisms of MRTF-Dependent Regulation of Bone Colonization by Breast Cancer Cells

David M. Gau, Quanhong Sun, Pooja Chawla, Ian Elder, Marion Joy, Peter C. Lucas, David N. Boone, Deborah L. Galson, Partha Roy

JOURNAL OF BONE AND MINERAL RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Enabling mRNA medicine for brain tumors

Saigopalakrishna S. Yerneni, Juliana H. Azambuja, Peter C. Lucas, Linda McAllister-Lucas, Kathryn A. Whitehead

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Dual benefit of MALT1 blockade in glioblastoma

Juliana Hofstatter Azambuja, Saigopalakrishna S. Yerneni, Gabriela N. Debom, Lisa M. Maurer, Hannah E. Butterfield, Linda R. Klei, Gary Kohanbash, Peter C. Lucas, Linda M. McAllister-Lucas

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

MALT1 is activated by doxorubicin and mediates therapy resistance in triple-negative breast cancer

Maria Beecher, Dong Hu, Linda Klei, Jack Little, Linda M. McAllister-Lucas, Peter C. Lucas

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Association of stromal tumor infiltrating lymphocytes (sTILs) in pretreatment biopsies in different molecular subtypes of HER2+/ER+ breast cancer: Assessment of NRG Oncology/NSABP B-52

Katherine L. Pogue-Geile, Sai K. Maley, Rim S. Kim, Ying Wang, Roberto Salgado, Corey Lipchik, Huichen Feng, Reena S. Cecchini, Samuel A. Jacobs, Ashok Srinivasan, Eleftherios Terry Mamounas, Charles E. Geyer, Priya Rastogi, C. Kent Osborne, Soonmyung Paik, Norman Wolmark, Peter C. Lucas, Mothaffar Rimawi

CANCER RESEARCH (2023)

Add to Collection

Meeting Abstract Oncology

Uncovering molecular heterogeneity of mixed ductal and lobular carcinoma using digital spatial profiling

Osama Shiraz Shah, Azadeh Nasrazadani, Jennifer M. Atkinson, Celina Kleer, Priscilla F. McAuliffe, Rohit Bhargava, Jorge Reis-Filho, Peter C. Lucas, Adrian V. Lee, Steffi Oesterreich

CANCER RESEARCH (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.